Quality standards for preclinical research in cardio-oncology
Clicks: 3
ID: 327770
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
0.6
/100
3 views
2 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #330 of 334 articles by views in european heart journal
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 334 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Preclinical research in cancer therapy-related cardiovascular toxicity (CTR-CVT) is a major domain of cardio-oncology and has provided biological explanation for the cardiovascular adverse effects of many cancer therapies. However, the choice of the experimental models to investigate the mechanisms of CTR-CVT is often based on personal experience and opinion, rather than on established principles and available evidence. Moreover, presentation of methods and results is frequently approximate. This Scientific Statement outlines potential quality standards regarding methodology and reporting in preclinical cardio-oncology research, with the goal of promoting accurate, reliable, and reproducible studies. Quality standards are distinguished in first-tier, when considered essential for robustness unless there is a strong justification for their omission, and second-tier standards, when desirable, but not necessary. First-tier standards ensure credible, self-sustaining research, while second-tier ones enhance quality of investigations and accelerate understanding of CTR-CVT. Adherence to the proposed quality standards is expected to benefit researchers embarking on new investigations, facilitate funding allocation, and inform the development of novel oncological therapies, eventually moving cardio-oncology science forward.
| Reference Key |
openalex_W7210291996
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Pietro Ameri, Rosalinda Madonna, Ambra Costa, Uri Amit, Ioanna Andreadou, Aarti Asnani, Paul W. Burridge, Carolina Balbi, Gilles W. De Keulenaer, Paul C. Evans, Alessandra Ghigo, Borja Ibáñez, Lorenz H Lehmann, Pilar Martı́n, Giorgio Minotti, Wouter C. Meijers, Éric Morel, Doan Ngo, June‐Wha Rhee, Carol Ann Remme, Carlo G. Tocchetti, Peter van Der Meer, Zoltán V. Varga, Ioannis I. Verginadis, Gerard Walls, Johann Wojta, Teresa López Fernández |
| Journal | european heart journal |
| Year | 2026 |
| DOI |
10.1093/eurheartj/ehag609
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.